PolyNovo Limited
At PolyNovo we are driven by improving the outcomes of patients through development and provision of the best surgical solutions possible. PolyNovo develops innovative medical devices utilizing the patented bioabsorbable polymer technology Novosorb.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Internationally (various countries)
About Us
NovoSorb is a family of proprietary medical grade polymers that can be expressed in a variety of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products via established pathways.
NovoSorb BTM (Biodegradable Temporizing Matrix) is the first product commercialized by PolyNovo. In 2015, following the FDA 510(K) clearance of BTM, PolyNovo was awarded an $11 million contract and a further $25 million in funding from the US-based Biomedical Advanced Research and Development Authority (BARDA) to complete a trial with BTM for full thickness burns.
We have expanded our manufacturing facility and headquarters in Melbourne, Australia, establishing high quality processes, enabling product innovation and preparing for growth.
Our Origin
The NovoSorb polymer technology was developed to fulfil the need for a synthetic biodegradable product that could be safely used in medical devices. NovoSorb can be expressed as a soft or hard polymer with programmed resorbsion timeframes providing uniquely optimized devices for a variety of applications. PolyNovo’s first medical device using NovoSorb technology is NovoSorb BTM.
NovoSorb BTM (Biodegradable Temporizing Matrix) was invented and developed by PolyNovo using polymer technology originating from CSIRO (Commonwealth Science Industry Research Organization). CSIRO’s Biomaterials Team invented and assigned to PolyNovo a unique range of synthetic absorbable polymers for use in biomedical applications. PolyNovo has subsequently augmented this with further patents directed to absorbable polymers.
Following the 2002 terrorist bombings in Bali many survivors were airlifted to Australia for treatment, some with significant burns. It became apparent that an alternative dermal substitute was required, one of synthetic origin, in order to treat the kinds of delayed and colonized wounds the survivors suffered.
Dr Tim Moore, PolyNovo’s principal scientist, collaborated with Prof. John Greenwood from the Royal Adelaide Hospital in the development of NovoSorb BTM to meet demanding clinical requirements for a dermal matrix. This development included the characterization of the product with its microarchitecture, bonding layer and external sealing membrane. Today NovoSorb BTM is available for use in many countries throughout the world.
The NovoSorb polymer is the driving technology behind PolyNovo’s next generation of novel medical devices currently in development. These devices will bring clinical advances to multiple surgical applications such as hernia repair and breast reconstruction. Further details can be found here.